레베르 선천성 흑암시 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 5.9%로 성장할 전망이며, 13억 4,000만 달러로 성장이 예측됩니다. 예측 기간 성장은 유전자 치료에 대한 투자 증가, 유전성 망막질환 유병률 상승, 새로운 치료법에 대한 규제 당국의 승인, 임상시험 확대, 헬스케어 지출 증가가 원동력이 될 것으로 예상됩니다. 예측 기간 주요 동향으로는 CRISPR 기반 치료법의 대두, 바이오 기술 기업 간의 연계 강화, 개별화 의료 개발, 원격 안과의 성장, 망막 화상 기술의 진보 등을 들 수 있습니다.
유전성 망막 질환의 유병률 상승은 레베르 선천성 흑암시(LCA) 시장의 성장을 가속할 것으로 예측됩니다. 유전성 망막질환(IRD)은 시력을 관장하는 눈 안쪽의 광감수성 조직인 망막에 영향을 미치는 유전성 질환입니다. 이러한 질환의 증가는 유전자 검사 진보, 인지도 향상, 진단의 향상, 수명 연장에 기인하고 있습니다. 유전자 검사의 진보로 IRD 진단이 쉬워져 더 많은 사례가 특정되게 되었습니다. 레베르 선천성 흑암시는 유전자 변이 및 질환의 메커니즘을 밝힘으로써 유전성 망막질환의 이해를 높이고 표적요법과 치료의 개발에 공헌하고 있습니다. 예를 들어 2025년 1월 영국 의회 하원도서관에 따르면 2024년에는 영국에서 약 2만 5,000명이 유전성 망막질환에 이환돼 연간 2% 증가를 나타내고 있습니다. 그 결과 유전성 망막질환의 유병률 증가가 레베르 선천성 흑암시 시장의 성장을 견인하고 있습니다.
레베르 선천성 흑암시 시장의 각 회사는 시력 회복과 질병 관리를 개선하기 위해 RNA 기반 치료 개발에 점점 힘을 쏟고 있습니다. RNA 기반 치료법은 RNA 분자를 이용하여 유전적 과정을 표적으로 하고 질병을 치료합니다. 이들 치료법에는 mRNA 백신, siRNA 치료법, 안티센스 올리고뉴클레오타이드, RNA 압타머 등이 포함됩니다. 예를 들어 2025년 1월 프랑스 제약회사인 Laboratoires Thea S.A.S.는 유전성 망막질환 RNA 요법을 추진하는 사업부문인 Sepul Bio를 출범시켰습니다. 세퓨르 바이오사는 특히 레베르 선천성 흑암시 10(LCA10)에 대한 sepofarsen과 USH2A 관련 망막색소변성증에 대한 ultevursen을 타깃으로 하고 있습니다. ultevursen의 LUNA 페이즈 2b 임상시험에서 최초의 환자에의 투여에 성공한 것을 두고, 세파르바이오사는 이러한 드문 유전성 질환에 대한 대응으로 크게 전진할 태세를 갖추고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 레베르 선천성 흑암시 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 레베르 선천성 흑암시 시장 : 성장률 분석
- 세계의 레베르 선천성 흑암시 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 레베르 선천성 흑암시 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 레베르 선천성 흑암시 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 레베르 선천성 흑암시 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 유전자 치료
- 의약품
- 인공망막
- 보조기구
- 기타 치료법
- 세계의 레베르 선천성 흑암시 시장 : 발병 연령별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 선천성 레베르 선천성 흑암시(LCA)(출생시부터)
- 유아기 레베르 선천성 흑암시(LCA)(1-5세)
- 지발성 레베르 선천성 흑암시(LCA)(6세 이상)
- 세계의 레베르 선천성 흑암시 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 직접 입찰
- 소매 매출
- 세계의 레베르 선천성 흑암시 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 안과 클리닉
- 안과 연구센터
- 재택 케어 설정
- 기타 최종 사용자
- 세계의 레베르 선천성 흑암시 시장 : 유전자 치료 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- RPE65 유전자 치환 요법
- CRISPR 기반 유전자 편집
- AAV(아데노 관련 바이러스) 벡터 요법
- 새로운 실험적 유전자 치료
- 세계의 레베르 선천성 흑암시 시장 : 의약품 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 레티노이드 기반 치료법
- 신경보호제
- 항염증제
- 항산화요법
- 세계의 레베르 선천성 흑암시 시장 : 인공 망막 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 이식형 망막 칩
- 인공망막자극장치
- 바이오닉 아이 테크놀로지
- 세계의 레베르 선천성 흑암시 시장 : 보조 기구 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 저시력 보조구
- 스크린 리더 및 점자 디바이스
- 시각장애인을 위한 이동 보조구
- 세계의 레베르 선천성 흑암시 시장 : 기타 치료법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 줄기세포요법
- 광유전학에 기초한 치료
- 시각 재활 프로그램
- 영양과 식사 개입
제7장 지역별 및 국가별 분석
- 세계의 레베르 선천성 흑암시 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 레베르 선천성 흑암시 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 레베르 선천성 흑암시 시장 : 경쟁 구도
- 레베르 선천성 흑암시 시장 : 기업 프로파일
- Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
- Astellas Pharma Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Invitae Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
- Novelion Therapeutics Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Andelyn Biosciences Inc.
- CD Genomics Inc.
- Editas Medicine Inc.
- MeiraGTx Holdings plc
- Sangamo Therapeutics Inc.
- LKC Technologies Inc.
- Aldeyra Therapeutics Inc.
- Asper Biogene OU
- Allergan Inc.
- ProQR Therapeutics NV
- GenSight Biologics SA
- Ocugen Inc.
- IVERIC bio Inc.(formerly Ophthotech Corporation)
- Atsena Therapeutics Inc.
- HuidaGene Therapeutics Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 레베르 선천성 흑암시 시장(2029년) : 새로운 기회를 제공하는 국가
- 레베르 선천성 흑암시 시장(2029년) : 새로운 기회를 제공하는 부문
- 레베르 선천성 흑암시 시장(2029년) : 성장 전략
제36장 부록
AJY
Leber congenital amaurosis (LCA) is an inherited eye disorder that leads to significant vision impairment or blindness from a young age, caused by genetic mutations that hinder the retina's ability to process light. The condition is marked by weak visual responses, involuntary eye movements (nystagmus), and severe farsightedness due to malfunctioning photoreceptors and gradual retinal degeneration.
Treatment options for LCA primarily include gene therapy, medication, retinal prosthetics, assistive technologies, and other interventions. Gene therapy is a technique that uses genetic material to treat or prevent disorders such as LCA by fixing defective genes. LCA is classified based on the age of onset, including congenital LCA (present at birth), early childhood LCA (1-5 years old), and late-onset LCA (after 6 years). Medications for LCA are distributed through various means such as direct tenders and retail sales, and are used in hospitals, specialized eye clinics, ophthalmology research centers, and home care environments.
The leber congenital amaurosis market research report is one of a series of new reports from The Business Research Company that provides leber congenital amaurosis market statistics, including the leber congenital amaurosis industry global market size, regional shares, competitors with the leber congenital amaurosis market share, detailed leber congenital amaurosis market segments, market trends, and opportunities, and any further data you may need to thrive in the leber congenital amaurosis industry. This leber congenital amaurosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The leber congenital amaurosis market size has grown strongly in recent years. It will grow from $1.01 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth observed during the historical period can be attributed to factors such as increased awareness of rare eye diseases, greater government funding, enhanced diagnostic methods, the expansion of ophthalmic research centers, and patient advocacy efforts.
The leber congenital amaurosis market size is expected to see strong growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period is expected to be driven by higher investments in gene therapy, the rising prevalence of inherited retinal disorders, regulatory approvals for new treatments, the expansion of clinical trials, and an increase in healthcare spending. Key trends for the forecast period include the rise of CRISPR-based therapies, greater collaboration between biotechnology companies, the development of personalized medicine, the growth of teleophthalmology, and advancements in retinal imaging technologies.
The rising prevalence of inherited retinal diseases is expected to drive the growth of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are genetic disorders that affect the retina, the light-sensitive tissue at the back of the eye responsible for vision. The increase in these diseases can be attributed to advancements in genetic testing, greater awareness, better diagnosis, and longer life expectancy. Progress in genetic testing has made it easier to diagnose IRDs, resulting in more cases being identified. Leber congenital amaurosis has helped enhance the understanding of inherited retinal diseases by revealing genetic mutations and disease mechanisms, contributing to the development of targeted therapies and treatments. For example, according to the UK Parliament's House of Commons Library in January 2025, approximately 25,000 people in the UK were affected by inherited retinal diseases in 2024, marking a 2% annual increase. As a result, the growing prevalence of inherited retinal diseases is driving the growth of the leber congenital amaurosis market.
Companies in the leber congenital amaurosis market are increasingly focusing on developing RNA-based treatments to improve vision restoration and disease management. RNA-based therapies utilize RNA molecules to target genetic processes and treat diseases. These therapies include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Thea S.A.S., a French pharmaceutical company, launched Sepul Bio, a business unit dedicated to advancing RNA therapies for inherited retinal diseases. Sepul Bio is specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is poised to make significant progress in addressing these rare genetic disorders.
In October 2024, Ocuphire Pharma Inc., a US-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. This acquisition aims to create a leading clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs). Opus Genetics Inc. is a US-based company that specializes in developing gene therapies for IRDs.
Major players in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OU, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.
North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leber congenital amaurosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the leber congenital amaurosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The leber congenital amaurosis (LCA) market consists of revenues earned by entities by providing services such as clinical trial services, healthcare and patient support services, vision rehabilitation services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber congenital amaurosis (LCA) market also includes sales of retinal implants, diagnostic testing kits, assistive devices, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Leber Congenital Amaurosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on leber congenital amaurosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for leber congenital amaurosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leber congenital amaurosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Gene Therapy; Pharmaceutical Drugs; Retinal Prosthesis; Assistive Devices; Other Treatments
- 2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth); Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years); Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
- 3) By Distribution Channel:; Direct Tender; Retail Sales
- 4) By End User: Hospitals; Specialized Eye Clinics; Ophthalmology Research Centers; Home Care Settings; Other End Users
- Subsegments:
- 1) By Gene Therapy: RPE65 Gene Replacement Therapy; CRISPR-Based Gene Editing; AAV (Adeno-Associated Virus) Vector Therapy; Emerging Experimental Gene Therapies
- 2) By Pharmaceutical Drugs: Retinoid-Based Therapies; Neuroprotective Agents; Anti-Inflammatory Drugs; Antioxidant Therapies
- 3) By Retinal Prosthesis: Implantable Retinal Chips; Artificial Retinal Stimulation Devices; Bionic Eye Technology
- 4) By Assistive Devices: Low Vision Aids; Screen Readers and Braille Devices; Mobility Aids for Vision Impairment
- 5) By Other Treatments: Stem Cell Therapy; Optogenetics-Based Treatments; Visual Rehabilitation Programs; Nutritional and Dietary Interventions
- Companies Mentioned: Sanofi S.A.; Novartis AG; Astellas Pharma Inc.; Invitae Corporation; Novelion Therapeutics Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Leber Congenital Amaurosis Market Characteristics
3. Leber Congenital Amaurosis Market Trends And Strategies
4. Leber Congenital Amaurosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Leber Congenital Amaurosis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Leber Congenital Amaurosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Leber Congenital Amaurosis Market Growth Rate Analysis
- 5.4. Global Leber Congenital Amaurosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Leber Congenital Amaurosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Leber Congenital Amaurosis Total Addressable Market (TAM)
6. Leber Congenital Amaurosis Market Segmentation
- 6.1. Global Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gene Therapy
- Pharmaceutical Drugs
- Retinal Prosthesis
- Assistive Devices
- Other Treatments
- 6.2. Global Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Congenital Leber Congenital Amaurosis (LCA) (From Birth)
- Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years)
- Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
- 6.3. Global Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Direct Tender
- Retail Sales
- 6.4. Global Leber Congenital Amaurosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialized Eye Clinics
- Ophthalmology Research Centers
- Home Care Settings
- Other End Users
- 6.5. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- RPE65 Gene Replacement Therapy
- CRISPR-Based Gene Editing
- AAV (Adeno-Associated Virus) Vector Therapy
- Emerging Experimental Gene Therapies
- 6.6. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Pharmaceutical Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Retinoid-Based Therapies
- Neuroprotective Agents
- Anti-Inflammatory Drugs
- Antioxidant Therapies
- 6.7. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Retinal Prosthesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Implantable Retinal Chips
- Artificial Retinal Stimulation Devices
- Bionic Eye Technology
- 6.8. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Assistive Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Low Vision Aids
- Screen Readers and Braille Devices
- Mobility Aids for Vision Impairment
- 6.9. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Stem Cell Therapy
- Optogenetics-Based Treatments
- Visual Rehabilitation Programs
- Nutritional and Dietary Interventions
7. Leber Congenital Amaurosis Market Regional And Country Analysis
- 7.1. Global Leber Congenital Amaurosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Leber Congenital Amaurosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Leber Congenital Amaurosis Market
- 8.1. Asia-Pacific Leber Congenital Amaurosis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Leber Congenital Amaurosis Market
- 9.1. China Leber Congenital Amaurosis Market Overview
- 9.2. China Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Leber Congenital Amaurosis Market
- 10.1. India Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Leber Congenital Amaurosis Market
- 11.1. Japan Leber Congenital Amaurosis Market Overview
- 11.2. Japan Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Leber Congenital Amaurosis Market
- 12.1. Australia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Leber Congenital Amaurosis Market
- 13.1. Indonesia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Leber Congenital Amaurosis Market
- 14.1. South Korea Leber Congenital Amaurosis Market Overview
- 14.2. South Korea Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Leber Congenital Amaurosis Market
- 15.1. Western Europe Leber Congenital Amaurosis Market Overview
- 15.2. Western Europe Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Leber Congenital Amaurosis Market
- 16.1. UK Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Leber Congenital Amaurosis Market
- 17.1. Germany Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Leber Congenital Amaurosis Market
- 18.1. France Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Leber Congenital Amaurosis Market
- 19.1. Italy Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Leber Congenital Amaurosis Market
- 20.1. Spain Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Leber Congenital Amaurosis Market
- 21.1. Eastern Europe Leber Congenital Amaurosis Market Overview
- 21.2. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Leber Congenital Amaurosis Market
- 22.1. Russia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Leber Congenital Amaurosis Market
- 23.1. North America Leber Congenital Amaurosis Market Overview
- 23.2. North America Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Leber Congenital Amaurosis Market
- 24.1. USA Leber Congenital Amaurosis Market Overview
- 24.2. USA Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Leber Congenital Amaurosis Market
- 25.1. Canada Leber Congenital Amaurosis Market Overview
- 25.2. Canada Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Leber Congenital Amaurosis Market
- 26.1. South America Leber Congenital Amaurosis Market Overview
- 26.2. South America Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Leber Congenital Amaurosis Market
- 27.1. Brazil Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Leber Congenital Amaurosis Market
- 28.1. Middle East Leber Congenital Amaurosis Market Overview
- 28.2. Middle East Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Leber Congenital Amaurosis Market
- 29.1. Africa Leber Congenital Amaurosis Market Overview
- 29.2. Africa Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Leber Congenital Amaurosis Market Competitive Landscape And Company Profiles
- 30.1. Leber Congenital Amaurosis Market Competitive Landscape
- 30.2. Leber Congenital Amaurosis Market Company Profiles
- 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Invitae Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novelion Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Leber Congenital Amaurosis Market Other Major And Innovative Companies
- 31.1. Andelyn Biosciences Inc.
- 31.2. CD Genomics Inc.
- 31.3. Editas Medicine Inc.
- 31.4. MeiraGTx Holdings plc
- 31.5. Sangamo Therapeutics Inc.
- 31.6. LKC Technologies Inc.
- 31.7. Aldeyra Therapeutics Inc.
- 31.8. Asper Biogene OU
- 31.9. Allergan Inc.
- 31.10. ProQR Therapeutics N.V.
- 31.11. GenSight Biologics S.A.
- 31.12. Ocugen Inc.
- 31.13. IVERIC bio Inc. (formerly Ophthotech Corporation)
- 31.14. Atsena Therapeutics Inc.
- 31.15. HuidaGene Therapeutics Co. Ltd.
32. Global Leber Congenital Amaurosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Leber Congenital Amaurosis Market
34. Recent Developments In The Leber Congenital Amaurosis Market
35. Leber Congenital Amaurosis Market High Potential Countries, Segments and Strategies
- 35.1 Leber Congenital Amaurosis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Leber Congenital Amaurosis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Leber Congenital Amaurosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
